Financing Liabilities - Additional Information (Details) - USD ($)	1 Months Ended		3 Months Ended			6 Months Ended
	Apr. 30, 2022	Apr. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Fair Value, Option, Quantitative Disclosures [Line Items]
Total funding received		$ 31,100,000
Percentage of funding received		25.00%
Funding expected to be received		$ 125,000,000.0
Financing liability, related party			$ 27,205,000			$ 27,205,000		$ 16,770,000
Financing liability			27,205,000			27,205,000		16,770,000
Gains (losses) on change in fair value of financing liability, related party			930,000	$ (496,000)	$ (500,000)	2,900,000	$ (496,000)
Change in fair value of financing liability						(5,800,000)	992,000
Gains (losses) on change in fair value of financing liability			930,000	(496,000)	$ (500,000)	2,900,000	(496,000)
Unrealized gains recognized within other comprehensive income related to change in instrument-specific credit risk			9,554,000			10,830,000
First Anniversaries [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Total funding received	$ 37,500,000
Percentage of funding received	30.00%
Second Anniversaries [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Funding expected to be received		$ 31,300,000
Percentage of funding expected to be received		25.00%
Third Anniversaries [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Funding expected to be received		$ 25,000,000.0
Percentage of funding expected to be received		20.00%
NovaQuest Funding Agreement [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Funding expected to be received		$ 62,500,000
Financing liability			27,200,000			27,200,000		16,800,000
Unrealized gains recognized within other comprehensive income related to change in instrument-specific credit risk			4,800,000	0		5,400,000	0
Bain Funding Agreement [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Total funding received	$ 18,750,000	$ 15,500,000
Percentage of funding received	30.00%	25.00%
Funding expected to be received		$ 62,500,000
Fees incurred		100,000
Financing liability, related party			27,200,000			27,200,000		$ 16,800,000
Unrealized gains recognized within other comprehensive income related to change in instrument-specific credit risk			$ 4,800,000	$ 0		$ 5,400,000	$ 0
NovaQuest and Bain Funding Agreements [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Fees incurred		200,000
Payable on funding agreement		$ 531,300,000
Contractual obligation description repayment timing						earlier of FDA approval or May 1, 2025
NovaQuest and Bain Funding Agreements [Member] | Minimum [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Percentage of funding commitment		300.00%
NovaQuest and Bain Funding Agreements [Member] | Maximum [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Percentage of funding commitment		425.00%